Christopher Bertke, OD
Optometrist · Edgewood, KYNPI 1528652831
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,150 of the $16,166 with a category attached, or 75.2%. Visioneering Technologies, Inc. accounts for 81.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $11,200 and has fallen 88.5% since, to $1,288 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $146.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Visioneering Technologies, Inc.$13K
- Bausch & Lomb Americas Inc.$663
- Alcon$612
- Coopervision Inc.$461
- Sun Pharmaceutical Industries Inc.$354
- Johnson & Johnson Vision Care, Inc.$306
- plus $627 from 11 others
What the payments were for
- Speaking & faculty fees$12,15075%
- Food & beverage$3,94024%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Visioneering Technologies, Inc. | 15 | $13,144 |
| Bausch & Lomb Americas Inc. | 24 | $663 |
| Alcon | 14 | $612 |
| Coopervision Inc. | 12 | $461 |
| Sun Pharmaceutical Industries Inc. | 14 | $354 |
| Johnson & Johnson Vision Care, Inc. | 11 | $306 |
| Eyevance Pharmaceuticals LLC | 2 | $215 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $118 |
| Oyster Point Pharma, Inc. | 4 | $93 |
| Biotissue Holdings Inc. | 2 | $51 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Harrow Eye, LLC | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $21 |
| Alimera Sciences, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Precision 1$338
- Tobradex ST$139
- MyDay Contact Lens$139
- Acuvue$125
- CEQUA$123
- Precision7$105
- INFUSE$104
- Multiple Brands Contact Lens$102
How this compares
$16,166 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $30,431 |
| XiidraLifitegrast | 15 | $23,449 |
| Cyclosporine | 20 | $19,058 |
| VyzultaLatanoprostene Bunod | 24 | $7,781 |
| Travoprost | 12 | $3,330 |
| Latanoprost | 85 | $685 |
| ErythromycinErythromycin Base | 24 | $298 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 41 | $296 |
| Timolol Maleate | 15 | $143 |
| Azithromycin | 15 | $45 |
| Brimonidine Tartrate | 16 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $663 | $31,23039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Edgewood
- Ian CarrEdgewood$6K
- Brooke HydeEdgewood$5K
- Paul KarpeckiLexington$3.6M
- Bilal AhmadLexington$150K
- Clay MattsonNicholasville$93K
- Ben LeonardCalvert City$75K
- Lee PeplinskiLouisville$74K
- Austin LifferthLouisville$72K
- Christopher KucLexington$52K
- Kristine Kerestan GarbigWilder$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.